It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
COMMENTARY
5 Companies Developing Japan-Made COVID-19 Jabs Face Challenges in Subject Enrollment, Trial Designs
A total of five companies big and small are competing to develop COVID-19 vaccines, which will be manufactured in Japan, with KM Biologics becoming the first to announce positive results from its PI/II study earlier this month. The focus is…
To read the full story
Related Article
- AnGes Jettisons Ancestral COVID-19 Vaccine Program
September 8, 2022
- AnGes COVID-19 Vaccine Falls Short in Clinical Trials, Focus Now on High Doses
November 8, 2021
- KM Biologics Moves Up COVID-19 Vaccine Target, Aims for Rollout in FY2022
September 22, 2021
- AnGes Launches PI/II Study for High-Dose COVID-19 Vaccine
August 18, 2021
- Daiichi Sankyo Begins Japan PI/II for mRNA COVID-19 Vaccine
March 23, 2021
- Shionogi Kicks Off Japan PI/PII Study of COVID-19 Vaccine Candidate
December 17, 2020
COMMENTARY
- LLP Info Might Become Inaccessible If New Coverage Rule Speeds Up Exit
September 10, 2024
- Japan’s Drug-Loss Landscape Is Transforming Driven by Private Sector
August 21, 2024
- How Will Simplified Delisting, Elective Care Affect G1 Withdrawal Scheme?
August 7, 2024
- Analysis: All Eyes Riveted on FY2024 Drug Price Survey for Off-Year Revision
August 6, 2024
- Lively Debate on Generic Industry Revamp Underway, All Eyes on Consortium Model
July 12, 2024
Long-listed products (LLPs) in Japan will be subject to a new health coverage scheme starting this October. This is expected…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…